Improving referral of patients for consideration of adjuvant chemotherapy after surgical resection of lung cancer

Current Oncology

Volumn 19, Issue 6, 2012, Pages

  Zuccato, J A ^a   Ellis, P M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Adjuvant chemotherapy; Health outcomes research; Knowledge transfer; Non small cell lung cancer; Quality improvement

Indexed keywords

AGED; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL PRACTICE; COHORT ANALYSIS; FEMALE; HEALTH CARE QUALITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD; PATIENT REFERRAL; RETROSPECTIVE STUDY; THORACOTOMY;

EID: 84870759705     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1133     Document Type: Article

References (27)

1. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2007. Toronto, ON: Canadian Cancer Society; 2007.
2. Tsuboi M, Ohira T, Saji H, et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2007;13:73-7.
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
4. Arriagada R, Bergman B, Dunant A, et al. on behalf of the International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
5. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol 2006;7:719-27. [Erratum in: Lancet Oncol 2006;7:797]
6. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
7. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage ib non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.
8. Douillard JY, Tribodet H, Aubert D, et al. on behalf of the LACE Collaborative Group. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 2010;5:220-8.
9. Alam N, Darling G, Evans WK, Mackay JA, Shepherd FA. on behalf of the Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. Crit Rev Oncol Hematol 2006;58:146-55.
10. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage ib and ii non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010;28:29-34.
11. Bouchard N, Laberge F, Raby B, Martin S, Lacasse Y. Adjuvant chemotherapy in resected lung cancer: two-year experience in a university hospital. Can Respir J 2008;15:270-4.
12. Kassam F, Shepherd FA, Johnston M, et al. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol 2007;2:39-43.
13. Younis T, Al-Fayea T, Virik K, Morzycki W, Saint-Jacques N. Adjuvant chemotherapy uptake in non-small cell lung cancer. J Thorac Oncol 2008;3:1272-8.
14. Booth CM, Shepherd FA, Peng Y, et al. Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a populationbased outcomes study. J Clin Oncol 2010;28:3472-8.
15. Cancer Quality Council of Ontario (CQCO). Hamilton Niagara LHIN [Web resource-see "Treatment" section, "Treating Lung Cancer According to Guidelines" item]. Toronto, ON: CQCO; 2010. [Most recent data available at: http://www.csqi.on.ca/Indicators%20by%20LHIN/hnhb_lhin/; cited August 2011]
16. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-17.
17. Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman AD. Does telling people what they have been doing change what they do? A systematic review of the effects of audit and feedback. Qual Saf Health Care 2006;15:433-6.
18. Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2006;:CD000259. [Update in: Cochrane Database Syst Rev 2012;6:CD000259]
19. O'Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007;:CD000409.
20. Winget M, Stanger J, Gao Z, Butts C. Predictors of surgery and consult with an oncologist for adjuvant chemotherapy in early stage nsclc patients in Alberta, Canada. J Thorac Oncol 2009;4:629-34.
21. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the lace Collaborative Group. J Clin Oncol 2008;26:3552-9.
22. Rogers EM. The Diffusion of Innovation. 4th ed. New York, NY: Free Press; 1995.
23. Prior M, Guerin M, Grimmer-Somers K. The effectiveness of clinical guideline implementation strategies-a synthesis of systematic review findings. J Eval Clin Pract 2008;14:888-97.
24. Groome PA, Bolejack V, Crowley JJ, et al. on behalf of the IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705.
25. Rami-Porta R, Ball D, Crowley J, et al. on behalf of the International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:593-602.
26. Kritchevsky SB, Simmons BP. Continuous quality improvement. Concepts and applications for physician care. JAMA 1991;266:1817-23.
27. Shortell SM, Bennett CL, Byck GR. Assessing the impact of continuous quality improvement on clinical practice: what it will take to accelerate progress. Milbank Q 1998;76:593-624,510.